PLoS ONE, 2021 Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved.
Yingyun Cai +5 more
doaj +2 more sources
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer [PDF]
Frontiers in Molecular BiosciencesDespite the efforts of researchers to develop new treatments for small cell lung cancer (SCLC), achieving effective treatment has not yet happened. Targeted therapy utilizing delta-like ligand 3 (DLL3), which is highly expressed in SCLC patients, holds ...
Mohammad Hossein Ataee +4 more
doaj +2 more sources
Immunotoxin Treatment of Cancer* [PDF]
Annual Review of Medicine, 2007 Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins.
Ira Pastan +2 more
exaly +3 more sources
Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin
OncoImmunology, 2019 Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors.
Patricia Guerrero-Ochoa +2 more
exaly +2 more sources
Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli [PDF]
AMB ExpressImmunotoxins are widely applied for cancer therapy. However, bacterial expression of immunotoxins usually leads to the formation of insoluble and non-functional recombinant proteins. This study was aimed to improve soluble expression of a novel anti-HER2
Sheida Mani +3 more
doaj +2 more sources
Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy [PDF]
Frontiers in MicrobiologyImmunotoxins (ITs), as targeted cancer therapies, confront limitations including off-target effects, immunogenicity, and inadequate tumor penetration, hindering clinical translation.
Quan Wang +10 more
doaj +2 more sources
Bacterial Protein Toxins as Anticancer Agents: Clinical Potential of Pseudomonas and Anthrax Toxins [PDF]
ToxinsProtein toxins are biologically active polypeptides produced by a variety of organisms, including bacteria, plants, fungi, and animals. These molecules exert potent and specific toxic effects on target cells and are primarily associated with ...
Richa Misra +6 more
doaj +2 more sources
Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells [PDF]
ImmunoAnalysis, 2021 Background: Tumor growth and progression depend largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). This receptor plays a significant role in the growth and survival of many solid tumors.
Khalil Hajiasgharzadeh +2 more
doaj +1 more source
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin [PDF]
Iranian Journal of Basic Medical Sciences, 2022 Objective(s): A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors ...
Mohammad Hosseininejad-Chafi +9 more
doaj +1 more source
Engineering and production of recombinant bovine pancreatic ribonuclease enzyme (RNase A) as a potential therapeutic [PDF]
مجله بیوتکنولوژی کشاورزی, 2021 Objective Immunotoxins are one of the most promising ways in therapeutic fields, specially cancer therapy which have a unique toxin-antibody structure, and kill the cancer cell by passing through the cell membrane and entering the target cell.
Masoume Vakili-Azghandi +3 more
doaj +1 more source